Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives $32.00 Average PT from Analysts

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) have received a consensus rating of “Moderate Buy” from the nine brokerages that are covering the company, Marketbeat Ratings reports. Six investment analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $32.00.

Several research firms recently issued reports on CPRX. Wall Street Zen downgraded Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Weiss Ratings raised shares of Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, June 3rd. HC Wainwright downgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $35.00 to $31.50 in a research note on Thursday, May 28th. Zacks Research cut Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 18th. Finally, Robert W. Baird lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 7th.

Catalyst Pharmaceuticals Price Performance

CPRX stock opened at $31.49 on Friday. Catalyst Pharmaceuticals has a 1 year low of $19.05 and a 1 year high of $32.56. The firm has a market capitalization of $3.86 billion, a PE ratio of 18.10, a price-to-earnings-growth ratio of 0.96 and a beta of 0.74. The business has a 50 day simple moving average of $31.09 and a 200-day simple moving average of $26.62.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Deerfield Management Company L.P. lifted its holdings in shares of Catalyst Pharmaceuticals by 72.8% in the 3rd quarter. Deerfield Management Company L.P. now owns 4,974,767 shares of the biopharmaceutical company’s stock valued at $98,003,000 after buying an additional 2,095,291 shares during the period. Janus Henderson Group PLC raised its holdings in shares of Catalyst Pharmaceuticals by 200.6% in the fourth quarter. Janus Henderson Group PLC now owns 1,719,767 shares of the biopharmaceutical company’s stock worth $40,124,000 after acquiring an additional 1,147,565 shares during the last quarter. Morgan Stanley raised its holdings in shares of Catalyst Pharmaceuticals by 59.1% in the fourth quarter. Morgan Stanley now owns 2,933,399 shares of the biopharmaceutical company’s stock worth $68,466,000 after acquiring an additional 1,089,775 shares during the last quarter. Bank of America Corp DE increased its position in Catalyst Pharmaceuticals by 38.0% during the 1st quarter. Bank of America Corp DE now owns 3,036,546 shares of the biopharmaceutical company’s stock worth $75,185,000 after purchasing an additional 836,704 shares in the last quarter. Finally, Fundsmith LLP raised its stake in Catalyst Pharmaceuticals by 24.2% in the 3rd quarter. Fundsmith LLP now owns 3,363,807 shares of the biopharmaceutical company’s stock valued at $66,267,000 after purchasing an additional 654,721 shares during the last quarter. 79.22% of the stock is owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).